Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
  • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
  • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
  • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
  • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• Congestive heart failure is a devastating disease where there is ineffective pumping of the heart leading to an accumulation of fluids in the lungs. Typical symptoms include shortness of breath, difficulty breathing when lying flat and swelling of legs and ankles. Said progressive impairment of physical fitness can ultimately lead to death. There are a number of causes for heart failure but the most frequent are myocardial infarction (about 60 percent of all cases), chronic hypertension (about 25 %), genetic disposition (10 %) and cardiomyopathy, or a combination of these factors.
• CHF chronic CHF
• the patients physical fitness determines the classification into NYHA I (no symptoms), NYHA Il (symptoms during moderate exertion), NYHA III (symptoms during mild exertion), or NYHA IV (symptoms at rest).
• the peroxisome proliferator activator receptors represent a class of nuclear hormone receptors, two of which (PPAR ⁇ and PPAR ⁇ ) are expressed in many tissues, including the myocardium and the vessels. Activation of the PPARs leads to expression of a variety of genes and, subsequently, production of proteins.
• the PPAR ⁇ activators e.g., rosiglitazone
• rosiglitazone have been approved for the treatment of type 2 diabetes mellitus, based on their efficacy in improving insulin sensitivity and delaying the progression of insulin resistance into overt diabetes (Malinowski and Bolesta Clin. Therapeutics (2000), 22, 1151-1168; Leff and Reed, Curr. Med. Chem.
• PPAR ⁇ activators the fibrates, are in clinical use because of their ability to reduce blood cholesterol levels (Sacks-FM, Am. J. Cardiol. (2001 ), 88(12A), 14N-18N). Novel PPAR ⁇ activators, which are structurally different from the fibrates and more potent, are in clinical development for lipid disorders and diabetes mellitus (Inoue and Katayama, Current Drug Targets: Cardiovascular & Haematological Disorders (2004), 4, 35-52).
• PPAR activators Apart from their metabolic effects, little is known about the direct effects of PPAR activators on the heart. In isolated neonatal cardiomyocytes in vitro, both the PPAR ⁇ activators fenofibrate and WY14,643 as well as the PPAR ⁇ activator rosiglitazone were able to prevent endothelin-1 induced hypertrophy. Similarly, the PPAR ⁇ activator reduced the hypertrophy induced by mechanical strain in isolated cardiomyocytes. In a model of arterial hypertension, PPAR ⁇ and PPAR ⁇ activation were both able to reduce cardiac fibrosis.
• PPAR ⁇ As well as PPAR ⁇ activation has been shown to reduce myocardial infarct size.
• PPAR ⁇ activators In the chronic phase after myocardial infarction, PPAR ⁇ activators have shown to improve myocardial remodelling and heart failure symptoms (Lianget al. Endocrinology 2003, 144: 4187-4194).
• heart failure may be worsened by PPAR ⁇ agonists in patients with type 2 diabetes mellitus.
• An embodiment of the present invention is the use of a compound of the formula (I)
• a further embodiment is the use of a compound of the formula (II)
• CHF congestive heart failure
• a preferred compound of the formula (II) is the compound of the formula (III)
• Suitable pharmaceutically acceptable salts are suitable for medical applications because of their greater solubility in water compared with the starting or base compounds. These salts must have a pharmaceutically acceptable anion or cation.
• Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids, and of organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p- toluenesulfonic and tartaric acids.
• Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts).
• physiologically functional derivative refers to any physiologically tolerated derivative of a compound of formula (I) of the invention, for . example, an ester which js able, on administration to a mammal such as, for example, a human, to form (directly or indirectly) a compound of formulae (I), (II) or (III) or an active metabolite thereof.
• Physiologically functional derivatives also include prodrugs of the compounds of the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may themselves have activity or not.
• the compounds of the invention may also-exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds of the invention belong within the scope of the invention and are a further aspect of the invention.
• the amount of a compound of formula (I), (II) or (III) necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient.
• the daily dose is generally in the range from about 0.3 mg to 100 mg (typically from about 3 mg to 50 mg) per day and per kilogram of body weight, for example about 3-10 mg/kg/day.
• An intravenous dose may be, for example, in the range from about 0.3 mg to 1.0 mg/kg, which can suitably be administered as an infusion of about 10 ng to 100 ng per kilogram and per minute.
• Suitable infusion solutions for these purposes may contain, for example, from about 0.1 ng to 10 mg, typically from about 1 ng to 10 mg, per millilitre.
• Single doses may contain, for example, from about 1 mg to 10 g of the active compound.
• ampoules for injections may contain, for example, from about 1 mg to 100 mg
• single-dose formulations that can be administered orally, such as, for example, capsules or tablets may contain, for example, from about 1.0 to 1000 mg, typically from about 10 to 600 mg.
• the compounds of formula (I), (II) or (III) may be used as the compound itself but they may also be in the form of a pharmaceutical composition with an acceptable carrier.
• the carrier is acceptable in the sense that it is compatible with the other ingredients of the composition and is not harmful to the patient's health.
• the carrier may be a solid or a liquid or both and is often formulated with the compound as a single dose, for example as a tablet, which may contain from about 0.05% to 95% by weight of the active compound.
• Other pharmaceutically active substances may likewise be present, including other compounds of formula 1.
• the pharmaceutical compositions of the invention can be produced by one of the known pharmaceutical methods, which may essentially consist of mixing the ingredients with pharmacologically acceptable carriers and/or excipients.
• compositions of the invention include those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the nature of the compound of formula (I), (II) or (III) used in each case.
• Coated formulations and coated slow-release formulations also belong within the framework of the invention. Preference is given to acid- and gastric juice-resistant formulations. Suitable coatings resistant to gastric juice comprise cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
• Suitable pharmaceutical compounds for oral administration may be in the form of separate units such as, for example, capsules, wafers, or tablets, each of which contain a defined amount of the compound of formula (I), (II) or (III); as powders or granules, as solution or suspension in an aqueous or non-aqueous liquid; or as an oil- in-water or water-in-oil emulsion.
• These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active compound and the carrier (which may consist of one or more additional ingredients) are brought into contact.
• the compositions are generally produced by uniform and homogeneous mixing of the active compound with a liquid and/or finely divided solid carrier, after which the product is shaped if necessary.
• a tablet can for example be produced by compressing or moulding a powder or granules of the compound, where appropriate with one or more additional ingredients.
• Compressed tablets can be produced by tableting the compound in free-flowing form such as, for example, a powder or granules, where appropriate mixed with a binder, glidant, inert diluent and/or one or more surface-active/dispersing agent(s) in a suitable machine.
• Molded tablets can be produced by moulding the compound which is in powder form and is moistened with an inert liquid diluent in a suitable machine.
• compositions which are suitable for peroral (sublingual) administration comprise tablets that contain a compound of formula (I), (II) or (III) with a flavoring, normally sucrose and gum Arabic or tragacanth, and pastilles which comprise the compound in an inert base such as gelatine and glycerol or sucrose and gum Arabic.
• compositions suitable for parenteral administration may comprise sterile aqueous preparations of a compound of formula (I), (II) or (III), which may be isotonic with the blood of the intended recipient. These preparations may be administered intravenously, although administration may also take place by subcutaneous, intramuscular or intradermal injection. These preparations can be produced by mixing the compound with water and making the resulting solution sterile and isotonic with blood. Injectable compositions of the invention generally contain from about 0.1 to 5% by weight of the active compound.
• compositions suitable for rectal administration may be in the form of single-dose suppositories. These can be produced by mixing a compound of formula (I) with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
• Pharmaceutical compositions suitable for topical use on the skin may be in the form of an ointment, cream, lotion, paste, spray, aerosol or oil.
• Suitable carriers are for example petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances.
• the active compound is generally present in a concentration of from about 0.1 to 15% by weight of the composition, for example from about 0.5 to 2%.
• compositions suitable for transdermal uses can be in the form of single plasters which are suitable for long-term close contact with the patient's epidermis.
• Such plasters suitably contain the active compound in an aqueous solution which is buffered where appropriate, dissolved and/or dispersed in an adhesive or dispersed in a polymer.
• a suitable active compound concentration is about 1 % to 35% by weight, or about 3% to 15%.
• a possibility is for the active compound to be released by electro-transport or iontophoresis as described, for example, in Pharmaceutical Research, 2(6): 318 (1986).
• both systolic and diastolic LV function - and therefore cardiac output - are improved after treatment with a compound of the formula (I), (II) or (III) but not with the PPAR ⁇ activator.
• PPAR ⁇ Activation of PPAR ⁇ also improved pulmonary congestion, as evidenced by the normalization of both right ventricular and lung weight (a lower lung weight is an indicator for better heart function; a high lung weight indicates pulmonary congestion, which is frequently due to depressed function of the heart (i.e., CHF).
• CHF depressed function of the heart
• the opposing effects of activation of these two PPAR subtypes in post myocardial infarction heart failure were therefore unexpected.
• One of the reasons for the discrepant findings could be tissue specific differential expression of the two PPAR subtypes.
• CHF congestive heart failure
• PPAR peroxisome proliferator activator receptor
• Example 1 Proof of concept study for use of a compound of the formula (I) for the treatment of congestive heart failure
• cardiac function was measured using an isolated working heart preparation (modified Langendorff apparatus, cf. Linz et al., J. Ren. Angiotensin Aldosterone Syst., 2003): The hearts were perfused according to Langendorff's method with an oxygenated (95% O2, 5% CO2) noncirculating Krebs- Henseleit solution of the following compositions (mmol/L): NaCI, 118; KCI, 4.7; CaCl2, 2.5; MgSO4, 1.6; NaHCO3, 24.9; KH2PO4, 1.2; glucose, 5.5; Na-pyruvate, 2.0.. The left atrium was cannulated by an incision of the left auricle.
• LV dP/dtmax is an index of myocardial contractility, i.e. the force generating ability of the heart; LV dP/dtmin is an index of the ability of the myocardium to relax.
• lung weight was measured as an index of pulmonary congestion, an indirect sign of CHF.
• the dual ACE/NEP, or vasopeptidase, inhibitor (7-(2-Acetylsulfanyl-3-methyl-butyrylamino)-6- oxo-1 ,2,3,4,6,7,8, 12b-octahydro-benzo[c]pyrido[1 ,2-a]azepine-4-carboxylic acid; international patent application no. WO 02/083671) that is known for being active in the treatment of CHF was applied in an additional group.
• HEK human embryo kidney
• the PPAR ⁇ reporter cell line was cultivated up to 80% confluence in DMEM medium (Life Technologies) with the following additives: 10% cs-FCS (foetal calf serum, Hyclone), antibiotics (0.5 mg/ml of zeozin [Invitrogen], 0.5 mg/ml of G418 [Life Technologies], 1% penicillin streptomycin solution [Life Technologies]) and 2 mM of L- glutamine (Life Technologies). Cultivation was carried out in standard cell culture bottles (Becton Dickinson) in a cell culture incubator at 37°C and 5% CO2.
• the 80% confluent cells were washed once with 30 ml of PBS (Life Technologies), treated with 2 ml of trypsin solution (Life Technologies) at 37 0 C for 2 min, taken up in 5 ml of the medium described above and counted in a cell counter. After dilution to 500,000 cells/ml, in each case 100,000 cells were sown into each well of a 96-well microtiter plate having a clear plastic bottom (Corning Costar). The plates were incubated in a cell incubator at 37°C and 5% CO2 for 24 h. Day 2: The PPAR ⁇ agonists to be tested were dissolved in DMSO at a concentration of 10 mM.
• This stock solution was diluted in Phenol-Red-free DMEM medium (Life Technologies) to which 5% of cs-FCS (Hyclone), 2 mM of L-glutamine (Life Technologies) and the antibiotics described above (zeozin, G418, penicillin and streptomycin) were added.
• Test substances were usually tested at 11 different concentrations (10 ⁇ M; 3.3 ⁇ M; 1 ⁇ M; 0.33 ⁇ M; 0,1 ⁇ M; 0.033 ⁇ M; 0.01 ⁇ M; 0.0033 ⁇ M; 0.001 ⁇ M; 0.00033 ⁇ M and 0.0001 ⁇ M). More potent compounds were tested in concentration ranges of from 1 ⁇ M to 10 pM or 100 nM to 1 pM.
• the medium of the PPAR ⁇ reporter cell line sown on day 1 was completely removed by aspiration, and immediately, the test substances diluted in medium were added to the cells. Dilution and addition of the substances can be carried out using a robot (Beckman Biomek 2000).
• the end volume of the test substances diluted in medium was 100 ⁇ l per well of a 96-well plate.
• the DMSO concentration in the assay was always below 0.1% v/v to prevent cytotoxic effects of the solvent.
• a standard PPAR ⁇ agonist which was also diluted to 11 different concentrations, was added to each plate.
• the test plates were incubated in an incubator at 37°C and 5% CO2 for 24 h.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cardiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Heart & Thoracic Surgery (AREA)
• Epidemiology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34927823

Family Applications (1)

Country Status (16)

Cited By (2)

Citations (5)

• 2004
  • 2004-12-17 EP EP04029946A patent/EP1671633A1/en not_active Withdrawn
• 2005
  • 2005-12-06 AT AT05824351T patent/ATE498400T1/de not_active IP Right Cessation
  • 2005-12-06 KR KR1020077013671A patent/KR20070086332A/ko not_active Withdrawn
  • 2005-12-06 MX MX2007006678A patent/MX2007006678A/es not_active Application Discontinuation
  • 2005-12-06 BR BRPI0519661-2A patent/BRPI0519661A2/pt not_active IP Right Cessation
  • 2005-12-06 AU AU2005315920A patent/AU2005315920A1/en not_active Abandoned
  • 2005-12-06 CA CA002590391A patent/CA2590391A1/en not_active Abandoned
  • 2005-12-06 WO PCT/EP2005/013046 patent/WO2006063715A1/en not_active Ceased
  • 2005-12-06 CN CNA2005800416904A patent/CN101072557A/zh active Pending
  • 2005-12-06 EP EP05824351A patent/EP1827425B1/en not_active Expired - Lifetime
  • 2005-12-06 JP JP2007545894A patent/JP2008524129A/ja not_active Withdrawn
  • 2005-12-06 DE DE602005026443T patent/DE602005026443D1/de not_active Expired - Lifetime
  • 2005-12-15 TW TW094144376A patent/TW200635584A/zh unknown
  • 2005-12-15 AR ARP050105284A patent/AR051723A1/es not_active Application Discontinuation
  • 2005-12-16 MY MYPI20055943A patent/MY141010A/en unknown
• 2007
  • 2007-06-10 IL IL183810A patent/IL183810A0/en unknown
  • 2007-06-14 US US11/762,799 patent/US7601863B2/en not_active Expired - Fee Related

Patent Citations (5)

Also Published As

Similar Documents

Legal Events